Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29164229 | 0.88 | PDGFRB (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL16401163 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL10319562 | 0.82 | ALDH1A1 (0.42) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL30669448 | 0.82 | ALDH1A1 (0.42) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL29164219 | 0.81 | PDGFRB (0.44) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL10320183 | 0.81 | TDP1 (0.45) | ALDH1A1MAPK1L3MBTL1TDP1POLB | |
| SCHEMBL428326 | 0.80 | GPR35 (0.42) | ALDH1A1MAPTTDP1POLBGABRA1 | |
| SCHEMBL9480791 | 0.80 | CA12 (0.40) | ALDH1A1MAPTMAPK1KDM4ESMN1; SMN2 | |
| SCHEMBL647368 | 0.79 | SMN1; SMN2 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL27883380 | 0.78 | SIRT6 (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1501817-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC | 2004-10-28 | — | — | US | disclosed |
| US-6756395-B2 | CYCLIZATION OF N-(4-CYANOMETHYLPHENYL)METHANESULFONAMIDES WITH ETHYLENEDIAMINE TO FORM N-(4-IMIDAZOL-2-YLMETHYL)-PHENYL) -METHANESULFONAMIDES; INCONTINENCE, SEXUAL DYSFUNCTION, NASAL CONGESTION, AND CNS DISORDERS; ALPHA 1 ADRENERGIC AGONISTS | ROCHE PALO ALTO LLC | 2004-06-29 | — | — | US | disclosed |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | ROCHE PALO ALTO LLC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003091236-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | RPS6KA1, RPS6KB1, RPS6KA6 | PDGFRB 1532/4885FGFR1 903/4885PDGFRA 1026/4885 |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | RPS6KA1, RPS6KB1, RPS6KA6 | PDGFRB 1532/4885FGFR1 903/4885PDGFRA 1026/4885 |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | PLK2, PLK3, DMPK | PDGFRB 234/4885FGFR1 1176/4885PDGFRA 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.